Maynard, S., Moore Simas, T., Bur, L., Crawford, S., Solitro, M., & Meyer, B. (2010). Soluble endoglin for the prediction of preeclampsia in a high risk cohort. Hypertension In Pregnancy: Official Journal Of The International Society For The Study Of Hypertension In Pregnancy, 29(3), 330-341. doi:10.3109/10641950902968684
Soluble Endoglin for the Prediction of Preeclampsia in a High Risk CohortHypertension in Pregnancy
AbstractOBJECTIVES: To evaluate soluble endoglin (sEng) and the soluble fms-like tyrosine kinase 1 (sFlt1) to placental growth factor (PlGF) ratio for the prediction of preeclampsia in high-risk women, and to evaluate differences in sEng between women with high-risk singleton and multiple gestation pregnancies. STUDY DESIGN: We collected serial serum specimens from 119 women at high preeclampsia risk. sEng, sFlt1 and PlGF were measured by ELISA. RESULTS: Among subjects who did not develop preeclampsia, mean serum sEng was significantly higher in those with multiple gestation pregnancies vs. high-risk singletons. Among women with singleton gestations, mean serum sEng was higher in subjects who developed early-onset (<34 >weeks) and late-onset (>or= 34 weeks) preeclampsia, as compared with subjects without preeclampsia, from 22 weeks and 28 weeks gestation onward, respectively. The within-woman rate of change of sEng was also higher in women who later developed preeclampsia. CONCLUSIONS: sEng is higher in women with multiple gestations vs. high-risk singleton pregnancies. In high-risk women, serum sEng is increased prior to preeclampsia onset.